„The Report Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 – Highly-Priced New Combination Products Forecast to Capture MarketResearchReports.biz „
GBI Research, a leading business intelligence provider, has released its latest research report „Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 – Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth“ The global COPD market is estimated to Current rating: $ 15.6 billion by 2019. Much of this growth will be fueled by a high number of new, more efficacious and convenient products In the market.
LABA / LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide / vilanterol and olodaterol / tiotropium. Despite recent patent expirations, including that of Advair Diskus (salmeterol / fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as observed in other indications.
This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition. Although the COPD market is characterized by low diagnosis rates, CPSD. Therefore, this has been added to market growth.
View Report At: http://www.marketresearchreports.biz/analysis/168797
Scope
A disease introduction, which defines the disease, including symptoms, diagnosis and treatment.
An analysis of the COPD marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map.
A detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial.
An in-depth forecasting model for the COPD market, which is the current marketed therapies, in addition to the potential market entry of new products. The model of a projected outcome, with high and low variance results, according to the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, cost and patent expirations.
Strategic consolidation within the COPD indicator is analyzed, which includes co-development and licensing agreements.
An overview of the drivers and barriers for the COPD market is also included.
Reasons to Buy
Primarily, the report will allow clients to gain a strong understanding of the COPD indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also allow you to:
Understand the COPD pipeline and the factors which indicate that it is becoming more innovative as well as the key pipeline molecules.
For more information, please visit this products webpage. This product was added to our catalog on Thursday 29 June, 2009.
Follow the trends in COPD clinical trials. In addition, the results of the study show that the study of COPD therapy has been shown to be more effective in the treatment of COPD.
Observe the potential growth patterns expected for the COPD market over the forecast period, and identify which countries are expected to contribute to this growth.
Download sample copy of this report at: http://www.marketresearchreports.biz/sample/sample/168797
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.7.1 Treatment Algorithm
2.8 GBI Research Report Guidance
3 Branded Products
3.1 Product Profile
3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc.
3.1.2 Advair Diskus – GlaxoSmithKline
3.1.3 Symbicort – AstraZeneca (co-promotion with Astellas Pharma Inc)
3.1.4 Combivent- Boehringer Ingelheim
3.1.5 Foradil – Novartis (Co-branded by Novartis and Schering Corporation)
3.1.6 Arcapta / Onbrez Breezhaler – Novartis
3.1.7 Daliresp-Nycomed
3.1.8 Seebri Breezhaler – Novartis
3.1.9 Striverdi Respimat – Boehringer Ingelheim
3.1.10 Relvar / Breo – GlaxoSmithKline / Theravance
3.1.11 Heat Map – Marketed Products Overview
4 COPD pipeline
4.1 Overview
4.2 Mechanisms of action in the pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Umeclidinium Bromide – GlaxoSmithKline
4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline / Theravance
4.4.3 Vilanterol Trifenate – GlaxoSmithKline / Theravance
4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim
4.4.5 TD-4208 – Theravance
4.4.6 QVA-149 – Novartis
4.4.7 Andolast (CR 2039) – Rottapharm | Madaus
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products
5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 United States
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the COPD Market
5.2.1 Drivers
5.2.2 Barriers
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one-stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: + 1-518-621-2074